TITLE

Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease

AUTHOR(S)
Calverley P M A; Lee A; Towse L; Van Noord J; Witek T J; Kelsen S
PUB. DATE
October 2003
SOURCE
Thorax;Oct2003, Vol. 58 Issue 10, p855
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
BACKGROUND: In chronic obstructive pulmonary disease (COPD), the degree of circadian variation in forced expiratory volume in 1 second (FEV(1)) and the influence of anticholinergic blockade is not known. Tiotropium is a long acting inhaled anticholinergic bronchodilator that increases daytime FEV(1) in COPD. We hypothesised that tiotropium would modify the overnight change in FEV(1), and this would be unaffected by the timing of drug administration. METHODS: A double blind, randomised, placebo controlled trial was conducted with tiotropium 18 mg once daily in the morning (09.00 hours), evening (21.00 hours), or an identical placebo. Patients with stable COPD (n=121, FEV(1)=41% predicted) underwent spirometric tests every 3 hours for 24 hours at baseline and after 6 weeks of treatment. RESULTS: There were no significant differences at baseline between the groups. Tiotropium improved mean (SE) FEV(1) (over 24 hours) in the morning (1.11 (0.03) l) and evening (1.06 (0.03) l) groups compared with placebo (0.90 (0.03) l), and nocturnal FEV(1) (mean of 03.00 and 06.00 hours) in the morning (1.03 (0.03) l) and evening (1.04 (0.03) l) groups compared with placebo (0.82 (0.03) l) at the 6 week visit (p<0.01). FEV(1) before morning or evening dosing was similar, while the peak FEV(1) moved later in the day with active treatment. The mean percentage change in FEV(1) from 09.00 hours to 03.00 hours (the nocturnal decline in FEV(1)) was -2.8% in the morning group, -1.0% in the evening group, and -12.8% in the placebo group. The magnitude of the peak to trough change in FEV(1) was not statistically different. CONCLUSIONS: Tiotropium produced sustained bronchodilation throughout the 24 hour day without necessarily abolishing circadian variation in airway calibre.
ACCESSION #
11054149

 

Related Articles

  • Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Calverley P M A; Lee A; Towse L; Van Noord J; Witek T J; Kelsen S // Thorax;Oct2003, Vol. 58 Issue 10, p855 

    BACKGROUND: In chronic obstructive pulmonary disease (COPD), the degree of circadian variation in forced expiratory volume in 1 second (FEV(1)) and the influence of anticholinergic blockade is not known. Tiotropium is a long acting inhaled anticholinergic bronchodilator that increases daytime...

  • Tiotropium beats LABA in COPD. Swan, David // Pulse;9/26/2012, Vol. 72 Issue 31, p14 

    The article presents a study according to which Tiotropium, an anticholinergic bronchodilator is more effective than a long-acting beta- agonist in preventing chronic obstructive pulmonary disease (COPD).

  • Inhaled Long-Acting β-Agonists Versus Anticholinergics in Older Patients With Chronic Obstructive Pulmonary Disease. Fabbri, Leonardo M.; Vogelmeier, Claus; Rabe, Klaus F.; Stanbrook, Matthew B.; Gershon, Andrea // Annals of Internal Medicine;10/18/2011, Vol. 155 Issue 8, p561 

    A letter to the editor is presented in response to the article "Comparison of inhaled long-acting β–agonist and anticholinergic effectiveness in older patients with chronic obstructive pulmonary disease: a cohort study," by A. Gershon and colleagues in an issue of 2011 and a response...

  • Anticholinergic drugs for COPD. Elliott, William T. // Infectious Disease Alert;May2011 Clinical Bri, p1 

    The article reports on the findings of a study published in the "New England Journal of Medicine" in 2011 which emphasize the benefits of using the anticholinergic drug tiotropium over the beta-agonist salmeterol in patients with moderate-to-very-severe chronic obstructive pulmonary disease (COPD).

  • Tiotropium for uncontrolled asthma.  // Neurology Alert;Dec2010 Supplement, p1 

    The article focuses on a study which investigated the therapeutic use of tiotropium, a long-acting anticholinergic inhaler, for patients with chronic obstructive pulmonary disease (COPD).

  • Tiotropium for Uncontrolled Asthma.  // Internal Medicine Alert;12/15/2010 Clinical Briefs, p1 

    The article reports on the findings of a study that suggest that tiotropium, a long-acting anticholinergic inhaler, has been approved for the treatment of chronic obstructive pulmonary disease.

  • Anticholinergic drugs for COPD. Elliott, William T. // Internal Medicine Alert;5/15/2011 Supplement, p1 

    The article reports on a study which shows the potential of anticholinergic drugs as first-line agents for the prevention of exacerbations in patients with chronic obstructive pulmonary disease (COPD).

  • Safety of Inhaled Anticholinergics for COPD Scrutinized.  // Internal Medicine Alert;10/29/2008 Pharmacology Watch, Vol. 30, p1 

    The article discusses the medical study which investigates the effects of inhaled anticholinergics by patients with chronic obstructive pulmonary disease (COPD).

  • Anticholinergic inhalers 'raise risk of CVD by 58%'. Tanday, Sanjay // GP: General Practitioner;9/26/2008, p8 

    The article offers information on the study conducted by the U.S. and Great Britain regarding the danger posed by anticholinergic inhalers to patients with chronic obstructive pulmonary disease (COPD). It was found that these patients are in danger of cardiovascular disease (CVD). Researchers...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics